CA2163250A1 - Biological adhesive composition and method of promoting adhesion between tissue surfaces - Google Patents

Biological adhesive composition and method of promoting adhesion between tissue surfaces

Info

Publication number
CA2163250A1
CA2163250A1 CA002163250A CA2163250A CA2163250A1 CA 2163250 A1 CA2163250 A1 CA 2163250A1 CA 002163250 A CA002163250 A CA 002163250A CA 2163250 A CA2163250 A CA 2163250A CA 2163250 A1 CA2163250 A1 CA 2163250A1
Authority
CA
Canada
Prior art keywords
tissue
adhesive composition
transglutaminase
biological adhesive
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002163250A
Other languages
French (fr)
Inventor
Kay Juergensen
Daniel Aeschlimann
Ernst B. Hunziker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orthogene Inc
Original Assignee
Kay Juergensen
Daniel Aeschlimann
Ernst B. Hunziker
Orthogene, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kay Juergensen, Daniel Aeschlimann, Ernst B. Hunziker, Orthogene, Inc. filed Critical Kay Juergensen
Publication of CA2163250A1 publication Critical patent/CA2163250A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1025Acyltransferases (2.3)
    • C12N9/104Aminoacyltransferases (2.3.2)
    • C12N9/1044Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001Use of materials characterised by their function or physical properties
    • A61L24/0015Medicaments; Biocides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10Polypeptides; Proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10Polypeptides; Proteins
    • A61L24/106Fibrin; Fibrinogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254Enzymes, proenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412Tissue-regenerating or healing or proliferative agents
    • A61L2300/414Growth factors
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/834Urine; urinary system
    • Y10S530/835Kidney
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/84Bones; tendons; teeth; cartilage
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/841Muscles; heart
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/842Skin; hair; nails; sebaceous glands; cerumen
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/843Digestive system
    • Y10S530/846Liver
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/85Reproductive organs or embryos

Abstract

A formulated biological adhesive com-position utilizes tissue transglutaminase in a pharmaceutically acceptable aqueous carrier.
The tissue transglutaminase is used in an ef-fective catalytic amount to promote adhesion between tissue surfaces upon treatment thereof by catalyzing the reaction between glutaminyl residues and amine donors of the tissue and/or the enzyme. The carrier contains a divalent metal ion such as calcium to promote said re-action.

Description

W094/~949 2 1 6 3 2~5 0~ ~

BIOLOGICAL ADHESIVE COMPOSITION AND METHOD OF PROMOTING
ADHESION 8~1h~N TISSUE SURFACES
CAL FIELD OF THE lNv~L.llON
This invention relates to the employment of biological adhesives in surgery. There are many situations within the different surgical specialties where the application of a biological glue would be beneficial. A biological glue can be used to stop a haemorrhage in general surgery, reconstruct nerve ruptures in neurosurgery, adhere skin and cartilage transplants and defects in plastic surgery, treat pneumothorax and/or fistulas in general or thoracic surgery, support vascular and intestinal anastomoses in vascular and general surgery, etc.
In orthopedic surgery, possible applications of a biological sealant include the treatment of chondral- and osteochondral fractures, transplantation of chondral or osteochondral materials, treatment of osteochondritis dissecans, joint fractures, meniscal tears as well as ruptured ligaments, tendons, myotendineous junctions or muscles. Furthermore, the polymerization and adhesion of biomatrix implants, being composed e. g. of collagen, gelatin, fibrinogen, W094/28949 PCT~S94/06208 ~
2 1 6 3 2r 5~

fibrin, or also macromolecules that are not tissue transglutaminase substrates such as polylactates etc.
and possibly containin~ various additives such as cell-attachment proteins, growth ~actors, cells etc., to tissue defects in orde;7~ enhance and stimulate the healing processes. Th~s latter application of the new biological sealant is of a particular importance.
This invention pertains to a formulated biological adhesive composition, its method of preparation and application. The adhesive composition is based on a particular mode of use of tissue transglutaminase (tTG = transglutaminase II
transglutaminase type C) in a pharmaceutically acceptable carrier. The value of the invention has been documented by biomechanical ~esting of adhesiveness between connective tissue surfaces.
BACRGROUND OF ~HE 1 N V ~N-l' 1 ON
Cartilage covers all articulating surfaces and does, due to its unique structure, endow a joint with nearly frictionless motion. The coefficient of friction, defined as ~=frictional force (F)/applied load (W), for articular cartilage in a diarthrodial joint is 0.00S-0.02 (human knee). As a comparison, the coefficient of friction for ice on ice is around five times higher (0.01-0.1), Mow, V. C., A. Ratcliffe and A. R. Poole "CARTILAGE AND DIARTHRODIAL JOINTS AS
PARADIGMS FOR HIERARCHICAL MATERIALS AND STRUCTURES"
Biomaterials, 13(2): 67-97 (1992).

~ W094/28949 PCT~S94/0620~
2 1 6 3 2~Q ~ ~ r The matrix of articular cartilage consists of 60-80~ water (and dissolved ions and gases) by wet weight of articular cartilage and 20-40% structural molecules like collagen, proteoglycans, glycosaminoglycans and glycoproteins. Chondrocytes, the specialized cells in articular cartilage, are embedded in this matrix and occupy only about 10% of the volume and articular cartilage contains neither nerves nor lymphatic vessels nor blood vessels, Buckwalter, J. A., L. C. Rosenberg and E. B. Hunziker, "ARTICULAR CARTILAGE: COMPOSITION, STRUCTURE, RESPONSE
TO INJURY, AND METHODS OF FACILITATING REPAIR", reprinted in ARTICULAR CARTILAGE AND KNEE JOINT
FUNCTION: BASIC SCIENCE AND ARTHROSCOPY New York, Raven Press (1990) and Hunziker, E. B.
"STRUKTURMOLEKULE DES KNORPELGEWEBES, DER SEHNEN UND
BANDER, Kniegelenk und Kreuzbander, Berlin, Springer ( 1990) -Two types of articular lesions can be differentiated. First, the chondral or superficial defect; this does not extend to or damage the subchondral bone. The subchondral bone is innervated, contains blood vessels, and connects the articular cartilage to the bone and bone marrow. Superficial cartilage lesions, not extending to the subchondral bone (i. e. partial thickness defects), may appear as a linear-crack type, a stellate fracture, a flap type, a fibrillation type, Bauer, M. and R. W. Jackson W094/28949 PCT~S94/06208 ~
21 6325~ -"CHONDRAL LESIONS OF THE FEMORAL CONDYLES: A SYSTEM OF
ARTHROSCOPIC CLASSIFICATION" Arthroscopy, 4(2):97-102 (1988). Cartilage lesions are often of traumatic origin but do also oc~u~r without any obvious cause.
Because of the lack of nerve supply, they usually do not cause pain. If symptoms occur, they are detected as delayed swelling of the synovium (the inner side of the joint capsule), with a intermittent locking as a result of a chondral fragment, or as recurrent effusions and crepitus, Scott, W. N. and J. N. Insall "INJURIES OF THE KNEE", reprinted in ROCKWOOD AND
GREEN'S FRACTURES IN ADULTS, Philadelphia, ~.B.
Lippincott Company (1991). Such defects are notorious as they do not heal, do not show propensity for repair reactions, and show many similarities to the early stages of degenerative joint diseases, such as osteoarthritis. Secondly, the full-thic~ness defect;
this extends to the subchondral bone, which contains nerves and blood vessels. It results for example from heavy trauma as a crater- or degrading type (Bauer et al, su~ra), or occurs in late stages of degenerative joint diseases, such as osteoarthritis. A symptom is often severe pain. Bleedings and repair reactions may occur, resulting in a vascularized fi~rous type of cartilage which is however not sufficient to support joint function. Such repair tissue very rarely persists (Buckwalter et al, supra).

~ W094/28949 2 1 6 3 2 ~ O PCT~Sg4/06208 , . I .;

Currently, stlll various attempts are made to facilitate cartilage repair in chondral and subchondral defects. One approach is to drill through chondral defects into the subchondral bone which induces bleeding, Pridie, K. H. "A METHOD OF RESURFACING
OSTEOARTHRITIC KNEE JOINTS" J Bone Joint Surg (Br) 41-B: 618-619 (1959). Through the bleeding repair reactions are induced and fibrocartilage is formed, but this tissue shows insufficient biomechanical properties and lacks long term persistence, Mitchell, N. and N.
Shepard "THE RESURFACING OF ADULT RABBIT ARTICULAR
CARTILAGE BY MULTIPLE PERFORATIONS THROUGH THE
SUBCHONDRAL BONE" J Bone and Joint Surq 58-A: 230-Z33 (1976). Resurfacing of articular cartilage defects with periosteal and perichondrial grafts has been evaluated, Coutts, R. D., S. L. Y. Woo, D. Amiel, H. P.
Von Schroeder and M. K. Kwan "RIB PERIOCHONDRIAL
AUTOGRAFTS IN FULL-THICKNESS ARTICULAR CARTILAGE
DEFECTS IN RABBITS" Clin Orthop 263-273 (1992);
Homminga, G. N., S. K. Bulstra, P. S. M. Bouwmeester and A. J. Van Der Linden "PERICHONDRAL GRAFTING FOR
CARTILAGE LESIONS OF THE KNEE" J Bone Joint Surg (Br) 72-B(6): 1003-7 (1990); Homminga, G. N., T. J. van der Linden, E. A. W. Terwindt-Rouwenhorst and J. Drukker, "REPAIR OF ARTICULAR DEFECTS BY PERICHONDRIAL GRAFTS:
EXPERIMENTS IN THE RABBIT" Acta Orthop Scand 60(3):
326-329 (1989) and O'Driscoll, S. W., F. W. Keeley and R. B. Salter "DURABILITY OF REGENERATED ARTICULAR

W094/28949 ~ ~ PCT~S94/06208 ~
21 63250 - ` -~ 6-CARTILAGE PRODUCED BY FREE AUTOGENOUS PERIOSTEAL GRAFTS
IN MAJOR FULL-THICKNESS DEFECTS IN JOINT SURFACES UNDER
THE INFLUENCE OF CO ~ INUOUS PASSIVE MOTIONI' J Bone and Joint Surg 70-A(4): 595-606 (1988). Perichondrium and periosteum are thin connective tissue layers which cover fibrocartilage or bone, respectively. Most investigators suture the perichondrium or periosteum into a subchondral defect, thereby creating additional cartilage damage. Others obtained good results by gluing perichondrium onto chondral defects of rabbits knee joints using a commercial fibrin sealant (Tissucol), Homminga, G. N., T. J. van der Linden, E. A. W. Terwindt-Rouwenhorst and J. Drukker, "REPAIR
OF ARTICULAR DEFECTS BY PERICHONDRIAL GRAFTS" Acta Orthop Scand 60(3): 326-329 (1989), an approach that did, however, require a two week immobilization of the joint. Joint immobilization has also been recommended when using fibrin sealant for the fixation of chondral or osteochondral fragments because of the poor resistance of the sealant to shear forces, Claes, L., C. Burri, G. Helbing and E. Lehner "BIOMECHANISCHE
UNTERSUCHUNGEN ZUR FESTIGKEIT VERSCHIEDENER
KNORPELKLEBUNGEN" Helv Chir Acta 48: 11-13 (1981). A
major argument against the use of fibrin sealant is the possible transmission of human pathogenic viruses, e.g., human immune deficiency virus (HIV) and hepatitis B virus. For this reason, fibrin sealants composed of ~ W094/28949 2 1 6 325 0 PCT~S94/06208 -7- ~ ~ t ~ , `
crude fractions of human blood plasma proteins are not permitted for use in the'Unitèd States.
Removal of fibrillated or irregular cartilage (shaving off) has been evaluated as a therapeutic approach, but it has been shown that shaved articular cartilage of the human knee joint will not regenerate and may even cause an increase of fibrillation and cell necrosis, Schmid, A. and F. Schmid "RESULTS AFTER
CARTILAGE SHAVING STUDIED BY ELECTRON MICROSCOPY" Am J
Sports Med 15(4): 386-387 (1987). Shaving of the patellar cartilage in rabbits does not lead to significant repair, Mitchell, N. and N. Shepard "EFFECT
OF PATELLAR SHAVING IN THE RABBIT" J Orthop Res 5: 388-392 (1987).
The use of cultured fetal chondrocytes embedded in a biomatrix containing fibrinogen, thrombin and additional components, Itay, S., A. Abramovici and Z. Nevo "USE OF CULTURED EMBRYONAL CHICK EPIPHYSEAL
CHONDROCYTES AS GRAFTS FOR DEFECTS IN CHICK ARTICULAR
CARTILAGE" Clin Orthop 220: 284-303 (1987), or of bone-marrow-derived mesenchymal stem cells, Pineda, S. J., T. Goto, V. M. Goldberg and A. I. Caplan "OSTEOCHONDRAL PROGENITOR CELLS ENHANCE REPAIR OF LARGE
DEFECTS IN RABBIT ARTICULAR CARTILAGE" Trans Orthop Res Soc 17 (2):598 (1992) as grafts, has been successful in chickens and induced full-thickness repair. It is not known whether successful transplantation of chondrocytes into superficial defects has occured in W094/28949 ~ PCT~S94/06208 ~

mammals or humans. The mechanical fixation (i. e.
local immobilization) of transplants remains a problem in this approach Curr`e~t treatment of cartilage fractures is often hampered by the failure of the tissue to adhere spontaneously. Stabilization of fragments with screws or Kirschner wires requires repeated surgical intervention, which results in additional trauma and destruction, and in spite of this, stable fixation is frequently not achieved. Cartilage frac~ures have to be reduced very precisely (best geometrical fit), otherwise fractures will heal through the formation of a fibrocartilage with insufficient biomechanical properties, Mitchell, N. and N. Shepard "HEALING OF
ARTICULAR CARTILAGE IN INTRA-ARTICULAR FRACTURES IN
RABBITS" J Bone and Joint Surg 62-A: 628-634 (1980).
Osteochondritis dissecans is an osteochondral lesion with an unknown, probably multifactorial etiology. Most patients with a loose osteochondral fragment in the ~oint have to undergo surgery, as nonoperative treatment has been shown to accelerate degenerative arthritis, Fede~ico, D. J., J. K. Lynch and P. Jokl "OSTEOCHONDRITIS DISSECANS OF THE KNEE: A
HISTORICAL REVIEW OF ETIOLOGY AND TREATMENT"
Arthroscopy 6(3): 190-197 (1990). The options for fixation of osteochondral fragments include the use of compression-screws, Kirschner wires, or a compression pinning system (hooked wires, anchoring screws, and ~ W094/28949 2 t ~ ~ 5 p PCT~S94/06208 bolts), Jakob, R. P. "THE TREATMENT OF OSTEOCHONDRITIS
DISSECANS OF THE KNEE JOINT USING A NEW COMPRESSION
WIRE SYSTEM" Z Unfallchir Versicherungsmed. 83t2): 104-110 (1990); Scott, D. J. and C. A. Stevenson 'IOSTEOCHONDRITIS DISSECANS OF THE KNEE IN ADULTS" Clin Orthop 76: 82-86 (1990) and Smilie, I. "OSTEOCHONDRITIS
DISSECANS, London, Livingston (1960). In most cases, a second operation is required in order to remove the metal. The usefulness of biological sealants in treatment of osteochondritis dissecans has not been evaluated so far.
The human meniscus is a discoid or semilunar slice of cartilaqe (consisting mainly of circumferentially orientated collagen fibers). It is present between joint surfaces, improves joint congruency and lessens point contact, as e.g. in the knee joint (Scott, W. N. and J. N. Insall, "INJURIES OF
THE KNEE", reprinted in ROCKWOOD AND GREEN'S FRACTURES
IN ADULTS, Philadelphia, J. B. Lippincott Company (1991). The central and inner part of the meniscus consists of an avascular, aneural and alymphatic fibrocartilage, Arnoczky, S. P. and R. F. Warren "MICROVASCULATURE OF THE HUMAN MENISCUS" Am J Sports Med 10(2): 90-95 (1982). Only meniscal tears that occur in the vascular periphery, and that are 3 cm in length or shorter, respond to mechanical suturing. In other types of meniscal tears, the inner meniscal portions are generally excised, a treatment that does W094/28949 ,= ~ PCT~S94106208 ~

in most cases lead j~to degenerative joint disease, (Scott, W. N. and~J. N. Insall "INJURIES OF THE KNEE", reprinted in ROCKWOOD AND GREEN'S FRACTURES IN ADULTS
Philadelphia, J. B. Lippincott Company (1991)). A
method for repairing all types of meniscal tears by use of an effective biological sealant would be of great clinical value. This would minimize, or even prevent, the high frequency of postoperative degenerative joint disease.
A number of substances are known to have the potential of stimulating chondrogenesis. For example, a collagen sponge implant can facilitate chondral repair! S~eer! D. P. ! M. Chvapil! R. G. Volz and M. D.
Holmes "ENHANCEMENT OF HEALING IN OSTEOCHONDRAL DEFECTS
BY COLLAGEN SPONGE IMPLANTS." Clin Orthop 144: 326-335 (1979). A number of proteins can promote chondrogenesis, like transforming growth factor beta, Seyedin, S. M., A. Y. Thompson and H. Bentz "CARTILAGE-INDUCING FACTOR-~: APPARENT IDENTITY TO
TRANSFORMING GROWTH FACTOR-~" J Biol Chem. 261(13):
5693-5695 (1986) and Sporn, M. B., A. B. Roberts and L. M. Wakefieland R. K. Assoiand "TRANSFORMING GROWTH
FACTOR-~: BIOLOGICAL FUNCTION AND CHEMICAL STRUCTURE"
Science 233: 532-534 (1986), fibroblast growth factor, Zapf, J. and E. R. Froesch "INSULIN-LIKE GROWTH
FACTORS/SOMATOMEDINS: STRUCTURE, SECRETION, BIOLOGICAL
ACTIONS AND PHYSIOLOGICAL ROLE" Horm Res 24: 121-130 (1986) and insulin-like growth factor, Hauschka, P. V., ~ WO 94128949 2 1 6 3~ 5 0 PCTIUS94/0620~
r~

A. E. Mavrakos and M. D. Iafrati "GROWTH FACTORS IN
BONE MATRIX: ISOLATION OF MULTIPLE TYPES BY AFFINITY
CHROMATOGRAPHY ON HEPARIN-SEPHAROSE" J Biol Chem 261(27): 12665-12674 (1986). Further work is required to identify the most useful factors and to find ways to deliver and anchor them into the site of injury (Buckwalter et al, suPra). An improved biological sealant could, however, greatly facilitate the clinical usefulness of such bioactive agents.
An effective biological sealant which may be used without risk of virus transmission, leading to hepatitis B or acquired immune deficiency syndrome (AIDS), would indeed open new therapeutic possibilities in all the situations described above.
S~MMARY OF THE lNv~;NllON
This invention is directed to a formulated biological adhesive composition and its method of use.
The composition contains tissue transglutaminase in a pharmaceutically acceptable aqueous carrier. The method is practiced by employing the composition containing tissue transglutaminase in an effective catalytic amount (100 ,ug/ml to 50 mg/ml) to promote adhesion between tissue surfaces upon treatment thereof by catalyzing the reaction between glutaminyl residues and amine donors of the tissue or in the enzyme itself.
The carrier also contains a divalent metal ion to promote said reaction.

W094/28949 -- PCT~S94/06208 2~ 63~0 ` ~

In a preferred form, the biological adhesive composition contains``~irssue transglutaminase in a pharmaceutically acceptable carrier having a pH of about 7 to about 8.5, a buffer and calcium (Ca~+') ions.
Further, the use of tissue transglutaminase does not require the inclusion of a proteolytic enzyme in the formulation and thus limits the risk of tissue damage (as for example induced by thrombin and plasmin present in fibrin sealant, etc.). The sealant composition may optionally contain one or more matrix forming proteins, such as fibronectin, or a growth factor such as transforming growth factor ~.
The tissue transglutaminase may be obtained from animal cells and cellular products. Tissue sources from which transglutaminase enzymes may be prepared for use in the biological sealant compositions consist of cells and cellular products including many organs and cell types of the human or animal body such as lung, liver, spleen, kidney, heart muscle, skeletal muscle, eye lens, endothelial cells, erythrocytes, smooth muscle cells, bone and macrophages.
The biological adhesive composition is particularly suited for use in the treatment of tissue surfaces in orthopedic or traumatological surgery.
Compositions may also be used in the treatment of biomatrices including cells embedded in a matrix where the matrix may be biodegradable or nonbiodegradable.
The biomatrices may also contain naturally occuring or W094/28949 2 1 63,2/5~ PCT~S94/06208 synthetic proteins having transglut~m;n~e substrate sites. Adhesion may be promoted between natural tissue surfaces and a biomatrix-coated implant material. The tissue transglut~m~n~se may be a recombinant DNA tissue transglut~m;n~se and, particularly, where the recombinant DNA has molecular regions that differ from a natural tissue transglut~mln~se without affecting its promotion of adhesion.
The above features of this invention and other embodiments of the sealant composition and its method of use will be further understood with reference to the following detailed description and Figures.

BRIEF DESCRIPTION OF THE FIGURES
Fig. 1 shows the influence of the shear force, needed for the displacement of cartilage cylinders at the relative incubation humidity of 50~;
incubation time: 10 minutes.
Fig. 2 shows the influence of the shear force, needed for the displacement of cartilage cylinders at the relative incubation humidity of 50~;
relative incubation time: 15 minutes.
Fig. 3 shows the influence of tTG-concentration on the shear force, needed for the displacement of cartilage cylinders at the relative incubation humidity of 50~.

SUBSTIME SHEET (RULE 28~

W094/28949 PCT~S94/06208 ~
2~Q

-13/a-Fig. 4 shows the influence of the shear force, needed for the d:isplacement of cartilage cylinders at the relatl~e incubation humidities of 50 or 80~; incubation time: 15 minutes.
Fig. 5 shows the influence of shear force, needed for the displacement of cartilage cylinders at a relative incubation humidity of 50~; incubation time: 10 minutes; with (tTG + CAC) or without (tTG) prior cartilage cylinder surface treatment by chondroitinase AC (CAC) during 5 minutes.
DET~Tr~T~'n DESCRIPTION
A. Tissue Transqlut~min~se Sources from which transglut~m;n~fie enzymes may be prepared for use in the biological sealant compositions consist of cells and cellular products including many organs and cell types of the human or animal body such as lung, liver, spleen, kidney, heart muscle, skeletal muscle, eye lens, endothelial cells, erythrocytes, smooth muscle cells, bone and macrophages. The tissue source of the enzyme may be selected or specifically adjusted to the individual medical indication. The term "tissue transglut~mln~Re"
(tTG = transglut~m;n~.~e II = transglut~m;n~se type C) or transglut~mln~se as used herein specifies this form of the enzyme independent of the cellular origin or post translational modiflcations, K. Ikura, T. Nasu, H.

SllBSTlTUTE SHEET (Rl.ILE 2B) ~ W094/28949 2 ~ 6 3 ~ ~ ~ PCT~S94/06208 Yokata, Y. Tsuchiya, R. Sasaki, and H. Chiba "AMINO
ACID SEQUENCE OF GUINEA PIG LIVER TRANSGLUTAMINASE FROM
ITS cDNA SEQUENCE." BIochemistry 27: 2898-2905 (1988).
The enzyme may be produced by recombinant DNA
technology and may be altered in regions not affecting the active site to obtain better conditions for application (e.g., storage stability, method for application, glutaminyl substrate quality, etc.), higher immunologic tolerance, or enzymatic capacity in certain cases.
B. PharmaceuticallY AccePtable Carrier or Media The tissue transglutaminase is formulated in a pharmaceutically acceptable aqueous carrier or media.
The carrier contains a buffering agent to maintain the pH in the range of about 7 to about 8.5. A Tris-buffer or HEPES-buffer may be employed. The preferred Tris-buffer is tris (hydroxymethyl) amino methane hydrochloride. Other types of buffers may be used, but it is desirable to exclude carbonate, acetate and phosphate buffers at high concentrations (or in excess over Ca2+ ions because of the low solubility of calcium ions in such buffers. Preferably calcium (Ca+~) ions are also present in a concentration above O.SmM, preferably about 50-lOOmM for cartilage, to promote the reaction. Strontium is another example of a divalent metal ion that may be used.

W094/28949 2 1 6 3 ~ 5 0 1 PCT~S94/06208 C. Matrix Protein The biological sealant composition may optionally contain a matrix-forming protein. The protein may be adjusted to the particular application in the amount and nature of the ingredients and is selected from the group consisting of collagen, fibrin, fibrinogen, fibronectin, entactin, osteonectin, osteopontin, thrombospondin, vitronectin, ~-lactoglobulin, and casein, and mixtures thereof. In general, any protein may optionally be employed in the sealant composition where it contains one or more amine acceptor sites for the tissue transglutaminase-catalyzed reaction.
D. Growth Factor The biological adhesive composition may also contain a growth factor selected from the group consisting of transforming growth factor ~ family, transforming growth factor ~ family, insulin-like growth factor family, epidermal growth factor, platelet-derived growth factor family, tumor necrosis factor family, fibroblast growth factor family and interleukins.
E. OrthoPedic~ ~raumatolo~ical, or Plastic Sur~ery APPlications The biological adhesive composition may be employed in the treatment of tissue surfaces in orthopedic or traumatological surgery selected from the group consisting of joint fractures, chondral defects, ~ W094/28949 ~ ~ PCT~S94/06208 superficial chondral defects (chondral defects), full-thickness defects, osteochondritis dissecans, meniscal tears, ligament tears, tendon tears, muscle lesions, myotendineous junction lesions, cartilage transplantation, bone transplantation, ligament transplantation, tendon transplantation, chondral transplantation, chondro-osseous transplantation, osseous transplantation, skin graft fixation, grafting (repairing) nerves and blood vessels, patching vascular grafts, microvascular blood vessel anastomosis, and treatment of combinations of said tissue surfaces.
(See Schlag, G. Rede, H. (Eds.) "FIBRIN SEALANT IN
OPERATIVE MEDICINE", Traumatoloqy Orthopaedics Vol. 7.
Springe Veslag, New York 1986).
F. Other APPlications The biological adhesive composition may be employed in other applications such as embryo transfer and applications such as for fibrin glue for the promotion of adhesion between a tissue surface and a biomatrix-coated implant material. The biomatrix implants may further contain a naturally occuring or synthetic protein having transglutaminase substrate sites. The matrix may be biodegradable or nonbiodegradable and the adhesive may be for use of cells embedded in the matrix (mesenchymal cells, chondroblasts, chondrocytes, stem cells, etc.). A
modification of the method may include the pretreatment of tissue surfaces with digestive enzymes may be used W094/28949 PCT~S94/06208 ~

to enhance adhesion. For instance, pretreatment of tissue surfaces with chondroitinase AC or ABC and/or other digestive enzymes to enhance the availability of substrates for the tissue transglutaminase and - r~
therefore increase the gluing capacity (See Fig. 4).
MOLECUL~R BASIS FOR THE PROPOSED BIOLOGICAL SEALAN~
The method and composition of this invention employs crosslinking of tissue surface proteins by tissue transglutaminase under conditions that mimic physiological events and allow sealant action even without the addition of exogenous substrate proteins.
It differs from methods based on known commercially available sealants by the employment of tissue transglutaminase rather than factor XIII, the plasma transglutaminase. The biological sealants of this invention give a broader specificity and allow gluing of tissue surfaces by action of the enzyme alone without any other protein additives. The biological sealant has been found to give tissue adhesion which is stable to higher shear forces than those associated with commercially available sealant containing factor XIII.
The key substance in the inventive biological sealant is tissue transglutaminase, an enzyme that catalyses a chemical reaction by which proteins become crosslinked to form network-like polymers. It belongs to a large family of enzymes, designated transglutaminases which have been shown to have a wide W094/28949 2 ~ 6 ~ PCT~S94/06208 distribution amongst tissues and body fluids. Proteins are modified by transglutaminases during many physiological processes, e. g. in fibrin clots during hemostasis and wound healing, in cell membranes of terminally differentiated cells, in various types of extracellular matrices and in the formation of the cornified envelope of epidermis. While the biological function is known only in a few cases, the mechanism of action of transglutaminase is well characterized at the molecular level.
Transglutaminase (EC 2.3.2.13) catalyses a Ca2+-dependent acyl-transfer reaction in which new ~-amide bonds are formed between ~-carboxamide aroups of peptide-bound glutamine residues and various primary amines (Folk, J. E. "TRANSGLUTAMINASES" Ann Rev Biochem 49: 517-531 (1980); Folk, J. E. and J. S.
Finlayson "THE ~ -GLUTAMYL)LYSINE CROSSLINK AND THE
CATALYTIC ROLE OF TRANSGLUTAMINASES" Adv Protein Chem 31: 1-133 (1977) and Lorand, L. and S. M. Conrad "TRANSGLUTAMINASES" Mol Cell Biochem 58: 9-35 (1984).
A glutamine residue serves as acyl-donor and the most common acyl-acceptors are -amino groups of peptide-bound lysine residues (reaction scheme I) or primary amino groups of some naturally occurring (poly) amines, like putrescine or spermidine (reaction scheme II). In the first case the reaction results in the formation of ~-glutamyl--lysine crosslinks either in or between proteins. Reactions following the second scheme result W094/28949 ~ ~ PCT~S94/06208 ~
2 1 6325~

in modifications possibly affecting the biological activity and turnover of the protein but not in polymer formation.
Reaction Scheme I
P--( C~2 ) 2CONH2 + H,N- ( CH2 ) 4-P -- P - ( CH7 ) 2CONH- ( CH~ ) 4-P + NH3 glutamine protein bound lysine Reaction Scheme II
P--( CH2 ) 2CONH, + H7N-R ~ P--( CH7 ) 2CONH -R + NH
glutamine primary amine where P=protein and R=organic side chain of variable structure.
The number of proteins acting as glutaminyl substrates is highly restricted, as both primary structure and conformation determine whether a glutamine residue is reactive or not. In contrast, the tolerance to structural differences in acyl-acceptors is considerable, as the only requirement is the presence of a -(CH2)4-NH2 group. This explains why both protein bound lysine residues and small primary amines may serve as amine donors. Thus, in a particular tissue only a small subset of proteins are glutaminyl substrates for the enzyme, whereas most proteins of the tissue are able to contribute ~-amino groups of lysine residues to serve as acyl acceptors in the crosslinking reaction. Furthermore, the specificity for different glutaminyl substrates varies depending on the type of transglutaminase. Several types of transglutaminase 1 63250 ' ~ ~ ' may recognize a single protein as substrate, but often with different affinity and/or with specificity for different glutamine residues. Certain proteins may serve as substrates only for a single member of the transglutaminase family. Factor XIII, the plasma transglutaminase, is an essential component of the commercially available fibrin sealants, but acts on a much more restricted group of protein-bound glutamines than tissue transglutaminase Gorman, J. J. and J. E.
Folk "STRUCTURAL FEATURES OF GLUTAMINE SUBSTRATES FOR
TRANSGLUTAMINASES" J Biol Chem 256(6): 2712-2715 (1981) and Gorman, J . J. and J. E. Folk "STRUCTURAL FEATURES
OF GLUTAMINE SUBSTRATES FOR TRANSGLUTAMINASES" J Biol Chem 259(14): 9007-9010 (1984). Tissue transglutaminase is a mainly intracellular enzyme with a broad tissue distribution, Greenberg, c. s., P. J.
Birckbichler and R. H. Rice "TRANSGLUTAMINASES:
MULTIFUNCTIONAL CROSS-LINKING ENZYMES THAT STABILIZE
TISSUES" FASEB J5: 3071-3077 (1991) .
The sealant of this invention employs tissue transglutaminase rather than factor XIII, a major advantage being that its broad substrate specificity gives a stronger adhesion. Factor XIII exists as a tetramer, a2b2 (Mr-320'000), composed of a dimer of the catalytic a-subunit (Mr~83'000 each) and two regulatory b-subunits (Mr~80'000) when circulating in the blood plasma, or as a dimer of only the a-subunit in, e. ~.
platelets, leukocytes and placenta Carrell, N. A., H.

W094/28949 PCT~S94/06208 21 63250 ~ ~-P. Erickson and J. McDonagh "ELECTRON MICROSCOPY AND
HYDRODYNAMIC PROPERTTES OF FACTOR XIII SUBUNITS" J Biol Chem 264(1): 551-~6~-(1989). The a-subunit of factor XIII has a high degree of sequence homology to tissue transglutaminase but the proteins are derived from different genes, Ichinose, A., R. E. Bottenus and E. W.
Davie "STRUCTURE OF TRANSGLUTAMINASES" J Biol Chem 265(23):13411-13414 (1990). Factor XIII is a zymogen, which is activated to factor XIIIa by thrombin cleavage and the following Cat2 dependent dissociation into active a-subunits and inactive b-subunits. The commercially available fibrin sealants are composed of a partially purified fraction of human blood plasma containing the active agents factor XIII, fibrinogen, fibronectin, thrombin, CaCl2.
The abundant tissue transglutaminase is a monomeric globular protein with a molecular mass of about 77'000 (Greenberg et al, su~ra and Ichinose, et al, suPra) and does, in contrast to factor XIII, not re~uire proteolytic activation. This property makes reproducible applications easier. A number of agents like transforming growth factor ~ and insulin-like growth factor have previously been described to stimulate chondrogenesis and may be applied in concert with the inventive sealant to achieve optimal regeneration. We have recently shown that tissue transglutaminase is expressed in a variety of cartilages. Aeschlimann, D., Wetterwald, A., Fleisch, ~ W094/28949 PCT~S94/06208 2 1 6325o ~
. ,. ~ .

H., and Paulsson, M. "EXPRESSION OF TISSUE
TRANSGLUTAMINASE IN SKELETAL TISSUES CORRELATES WITH
EVENTS OF TERMINAL DIFFERENTIATION OF CHONDROCYTES", J Cell Biol, Vol. 120[6], page 1461 to 1470 (1993).
Tissue transglutaminase is likely to catalyze physiological crosslinks in cartilage, and in this respect the inventive sealant mimics a naturally occurring process. As a consequence both the enzyme and its reaction products occur in normal cartilage and are unlikely to be toxic. Transglutaminases catalyze protein crosslinking during formation of the cornified envelope forming the superficial layer of the epidermis, Thacher, S. M. and R. H. Rice "KERATINOCYTE-SPECIFIC TRANSGLUTAMINASE OF CULTURED HUMAN EPIDERMAL
CELLS: RELATION TO CROSS-LINKED ENVELOPE FORMATION AND
TERMINAL DIFFERENTIATION" Cell 40: 685-695 (1985). As the massive production of crosslinks does not induce an immunological response in the skin, it appears that the products formed by tissue transglutaminases are not immunogenic.
As an important prerequisite for application of the (tTG) enzyme in the highly collagenous skeletal tissues, collagens expressed in bone and tendon, type III (Bowness et al, 1987), and in cartilage, type II
(Aeschlimann et al, 1993, su~ra), are substrates for the tissue transglutaminase enzyme. The observation that several other extracellular substrate proteins are intimately associated with the vascular endothelium W094/28949 PCT~S94/06208 ~
21 63250 `
~23~
like entactin, Oisteonectin, (Aeschlimann, D. and M.
Paulsson "CROSS-LINKING OF LAMININ-NIDOGEN COMPLEXES BY
TISSUE TRANSGLUTAMINASE" J ~iol Chem 266: 15308-15317 (1991); Aeschlimann, D., Wetterwald, A., Fleisch, H., and Paulsson, M. "EXPRESSION OF TISSUE TRANSGLUTAMINASE
IN SKELETAL TISSUES CORRELATES WITH EVENTS OF TERMINAL
DI~FERENTIATION OF CHONDROCYTES", J Cell Biol (1993), in press), vitronectin, fibronectin and fibrin(ogen) (Greenberg, C. S., P. J. Birckbichler and R. H. Rice "TRANSGLUTAMINASES: MULTIFUNCTIONAL CROSS-LINKING
ENZYMES THAT STABILIZE TISSUES" FASEB J.5: 3071-3077 (1991)) extends the potential application range of tissue transqlutaminase to the repair of vascular lesions.
ExamPles An n vitro system for the quantitative evaluation of the adhesive strength of biological glues has been developed to be able to compare the adhesive strength obtained with commercially available formulations to that created by the biological sealant of this invention.
Tissue transglutaminase (tTG) was purified from guinea pig liver by means of DEAE-cellulose chromatography of liver homogenate supernatant, followed by protamine precipitation of the enzyme, selective extraction with ammonium sulfate solution, and rechromatography over a molecular sieve column, Connellan, J. M., S. I. Chung, N. K. Whetzel, L. M.

~W094/28949 ~ ~ PCT~S94/06208 2t632so Bradley and J. E. Folk "STRUCTURAL PROPERTIES OF GUINEA
PIG LIVER TRANSG~UTA~INASE" J Biol Chem 246(4): 1093-. ~ ~ .
1098 (1971). tTG was pooled and concentrated to 1 mg/ml in 10 mM Tris/acetate (pH 6.0), containing 1 mM
EDTA and lS0 mM NaCl, Aeschlimann, D. and M. Paulsson "CROSS-LINKING OF LAMININ-NIDOGEN COMPLEXES BY TISSUE
TRANSGLUTAMINASE" J Biol Chem 266: 15308-15317 (1991).
Tissue transglutaminase was compared to a commercially available fibrin glue (Tissucol) and three other types of controls (NaCl-solution, Tris-reaction buffer and incubation with no treatment). Tissucol consists of two solutions which are mixed prior to application. One part consists of 75-115 mq/ml fibrinogen, 2-9 mg/ml plasma fibronectin, 10-50 U/ml factor XIII and 40-120 ~g/ml plasminogen. The other one is made up of 4 IU thrombin in 53 mM CaCl~. After heating to 37OC and mixing, the two components are applied to the cartilage surfaces. Tissue transglutaminase glue consists of two solutions: A) tissue transglutaminase (1 mg/ml in 10 mM Tris/acetate, pH 6.0, 150 mM NaCl, 1 mM EDTA) and B) Tris reaction buffer (0.1 M CaCl2 in 10 mM Tris/HCl, pH 7.4, 300 mM
NaCl), which are applied to separate tissue surfaces and are mixed by joining the two tissue surfaces. A
0.9~ NaCl solution, Tris reaction buffer and not treated cartilage surfaces were used as controls.
Pretreatment with 4 ~1 Chondroitinase AC
(CAC) (Sigma), dissolved in phosphate-buffered saline W094/28949 2 1 6 3 2 5 0 PCT~S94/06208 (GIBCO) to an ~a~ ty of 1 U/~l, on each cartilage surface was performed at 37C in a wet chamber for 5 minutes, followed by thorough rinsing with phosphate-buffered saline and careful drying with cellucotton.
This pretreatment lead to a depolymerisation of glycosaminoglycans (chondroitin 4-sulphate and chondroitin 6-sulphate) and is therefore likely to have made accessible more substrate sides, carney, S. L.
~'PROTEOGLYCANS. CARBOHYDRATE ANALYSIS" Oxford, IRL
Press (1986).
Cartilage-bone cylinders with a diameter of 3.9mm were obtained with a myelotomy drill (Institute Straumann, Switzerland) from a bovine shoulder 10-20 hours after slaughter. 50% of the cartilage thickness was cut off perpendicularly to the long axis of the cylinder with a razor blade.
The surfaces were treated with 4 ~1 tTG
solution and 4 ~1 Tris reaction buffer, one drop of fibrin glue or 8 ~1 of the control solutions or left untreated. The two cartilage cylinders were immediately joined at their cut surfaces and an 80 g weight was applied vertically while the assembly was incubated at 37C in a humidified chamber (humidity 50 or 80%) for 10 or 15 minutes.
A controlled, linear, ramped shear force (0.27 N/s) was applied to the top cartilage cylinder.
The shear force was regulated via a signal generator (wavetech) and an amplifier, exerted by an ~ W094/28949 2 ~ 6 3~5 0 , s~ PCT~S94/06208 -.26-electromagnetic coil and a ferromagnetic bar, and measured with a specially designed load cell (precision 1. 0 X 10-3 N). The load cell was connected with a dynamic strain gauge amplifier (DMD 20 A, Hottinger Baldwin Messtechnik, Switzerland). 720 values in 3 seconds were recorded on a data logger (Mikromec, Suprag, Switzerland), from which they were transmitted to a computer (Macintosh LC). In parallel with the digitalization of the resulting force the input signal (linear up ramp) and the measured values can be visualized on an oscilloscope.
Application of the tTG to exposed surfaces of cylindrical cartilaae tissue examples produced a much higher adhesive effect than in the control groups where only NaCl-solution, Tris reaction buffer or no solution was applied (p < O.Ol, Wilcoxon signed-rank test) (Figure 1).
The same effect resulted after increasing the incubation time from lO minutes (Figure 1) to 15 minutes (Figure 2), although the shear force, especially in the NaCl group, showed a tendency to increase. Moreover, the adhesive effect produced was dependent on the concentration of tissue transglutaminase (see Figure 3).
A comparison of tTG with Tissucol showed a comparative gluing capacity at 50~ relative humidity, while much of the adhesive effect of Tissucol (but not of tTG) was lost when relative humidity was raised to W094/28949 2 1 6 3 2 5 0 PCT~S94/06208 80% (Figure 4). The sealant effect of tTG with prior application of chondroitinase AC is shown in Figure 5.
Other modifications or embodiments of this invention will be understood to a person of ordinary ~ :
skill in this art in view of the above description without departing from the scope of this invention.
What is claimed is:

Claims

(1) A formulated biological adhesive composition comprising tissue transglutaminase and a pharmaceutically acceptable carrier, said tissue transglutaminase in an effective amount to promote adhesion upon treatment of tissue in the presence of a divalent metal ion.

(2) The biological adhesive composition of claim 1 having a pH of about 7 to about 8.5, a divalent metal ion, and a buffering agent in an aqueous medium.

(3) The biological adhesive composition of claim 2 wherein said divalent metal ion is selected from the group consisting of calcium and strontium.

(4) The biological adhesive composition of claim 2 wherein said divalent metal ion is calcium.

(5) The biological adhesive composition of claim 4 wherein said calcium is present in an amount in the range of about 0.5mM to about 100mM.

(6) The biological adhesive composition of claim 1 wherein said tissue transglutaminase is obtained from an aggregate of animal cells and cellular products.

(7) The biological adhesive composition of claim 1 wherein said tissue transglutaminase is selected from the group consisting of epithelia, parenchymatous organs, connective or nervous tissue, muscle, cartilage, bone, lung, liver, spleen, kidney, heart muscle, skeletal muscle, eye lens, endothelial cells, smooth muscle cells and biomatrix to promote the adhesion of tissue correspondingly selected from said tissue group.

(8) The biological adhesive composition of claim 1 wherein said tissue transglutaminase is in an amount of about 100 µg/ml to about 50 mg/ml.

(9) The biological adhesive composition of claim 1 wherein said tissue transglutaminase is obtained from a tissue source selected from the group of cells and cellular products consisting of lung, liver, spleen, kidney, heart muscle, skeletal muscle, eye lens, endothelial cells, erythrocytes, smooth muscle cells, bone and macrophages to promote the adhesion of tissue correspondingly selected from said tissue group.

(10) The biological adhesive composition of claim 1 containing an additional protein.

(11) The biological adhesive composition of claim 10 wherein said protein is selected from the group consisting of collagen, fibrin, fibrinogen, fibronectin, entactin, osteonectin, osteopontin, thrombospondin, vitronectin, .beta.-lactoglobulin, and casein, and mixtures thereof.

(12) The biological adhesive composition of claim 1 containing a growth factor.

(13) The biological adhesive composition of claim 12 wherein said growth factor is selected from the group consisting of transforming growth factor .beta. family, transforming growth factor .alpha.
family, insulin-like growth factor family, epidermal growth factor, platelet-derived growth factor family, tumor necrosis factor family, fibroblast growth factor family and interleukins.

(14) The biological adhesive composition of claim 1 wherein said tissue transglutaminase is a recombinant DNA tissue transglutaminase.

(15) The biological adhesive of claim 14 wherein said recombinant DNA has molecular regions that differ from a natural tissue transglutaminase without affecting its promotion of adhesion.

(16) The biological adhesive composition of claim 1 for use in the treatment of tissue selected from the group consisting of joint fractures, chondral defects, superficial chondral defects, full-thickness defects, osteochondritis dissecans, meniscal tears, ligament tears, tendon tears, muscle lesions, myotendineious junction lesions, cartilage transplantation, bone tissue transplantation, ligament transplantation, tendon transplantation, chondral transplantation, chondro-osseous transplantation, skin graft fixation, grafting or repairing nerves and blood vessels, patching vascular grafts, and microvascular blood vessel anastomosis.
(17) The biological adhesive composition of claim 1 wherein said tissue comprises a biomatrix having transglutaminase substrate sites and containing cells or an embryo transfer system.

(18) The biological adhesive composition of claim 1 for use in the treatment of biomatrix implants further containing a naturally occurring or synthetic protein having transglutaminase substrate sites.

(19) The biological adhesive composition of claim 18 wherein said protein is selected from the group consisting of collagen, fibrin, fibrinogen, fibronectin, entactin, osteonectin, osteopontin, thrombospondin. vitronectin, .beta.-lactoglobulin, casein, and mixtures thereof.

(20) The biological adhesive composition of claim 1 for use in promoting the adhesion between tissue and a biomatrix-coated implant material.

(21) The biological adhesive composition of claim 20 wherein said tissue is selected from the group consisting of epithelia, parenchymatous organs, connective or nervous tissue, muscle, cartilage, bone, lung, liver, spleen, kidney, heart muscle, skeletal muscle, eye lens, endothelial cells, smooth muscle cells and biomatrix to promote the adhesion of tissue correspondingly selected from said tissue group.

(22) A method of promoting adhesion upon treatment of tissue comprising providing tissue for adhesion, and applying to said tissue an effective amount of tissue transglutaminase to promote adhesion of said tissue in the presence of a divalent metal ion.

(23) The method of claim 22 wherein said tissue transglutaminase is formulated in a pharmaceutically acceptable aqueous carrier having a pH of about 7 to about 8.5, a buffering agent and divalent calcium ion.

(24) The method of claim 23 wherein said calcium is present in an amount in the range of about 0.1 mM to about 100 mM.

(25) The method of claim 22 wherein said tissue transglutaminase (tTG) is obtained from a tissue source selected from the group of cells and cellular products consisting of lung, liver, spleen, kidney, heart muscle, skeletal muscle, eye lens, endothelial cells, erythrocytes, smooth muscle cells, bone and macrophages to promote the adhesion of tissue correspondingly selected from said tissue group.

(26) The method of claim 23 wherein said carrier contains a protein.

(27) The method of claim 26 wherein said protein is selected from the group consisting of collagen, fibrin, fibrinogen, fibronectin, entactin, osteonectin, osteopontin, thrombospondin, vitronectin, .beta.-lactoglobulin, and casein, and mixtures thereof.

(28) The method of claim 23 wherein said carrier contains a growth factor.

(29) The method of claim 28 wherein said growth factor is selected from the group consisting of transforming growth factor .beta.
family, transforming growth factor .sigma. family, insulin-like growth factor family, epidermal growth factor, platelet-derived growth factor family, tumor necrosis factor family, fibroblast growth factor family and interleukins.

(30) The method of claim 22 wherein said tissue transglutaminase is a recombinant DNA tissue transglutaminase.

(31) The method of claim 30 wherein said recombinant DNA has molecular regions that differ from a natural tissue transglutaminase without affecting its promotion of adhesion.

(32) The method of claim 22 for use in the treatment of tissue selected from the group consisting of joint fractures, chondral defects, superficial chondral defects, full-thickness defects, osteochondritis dissecans, meniscal tears, ligament tears, tendon tears, muscle lesions, myotendinous junction lesions, cartilage transplantation, bone transplantation, ligament transplantation, tendon transplantation, chondral transplantation, chondro-osseous transplantation, skin graft fixation, grafting or repairing nerves and blood vessels, patching vascular grafts, and microvascular blood vessel anastomosis.

(33) The method of claim 22 wherein said tissue comprises a biomatrix having transglutaminase substrate sites and containing cells or an embryo transfer system.

(34) The method of claim 22 for use in the treatment of biomatrix implants further containing a naturally occurring or synthetic protein having transglutaminase substrate sites.

(35) The method of claim 34 wherein said protein is selected from the group consisting of collagen, fibrin, fibrinogen, fibronectin, entactin, osteonectin, osteopontin, thrombospondin, vitronectin, .beta.-lactoglobulin, casein, and mixtures thereof.

(36) The method of claim 22 for use in promoting the adhesion between tissue and a biomatrix-coated implant material.

(37) The method of claim 22 wherein said tissue is selected from the group consisting of epithelia, parenchymatous organs, connective or nervous tissue, muscle, cartilage, bone, lung, liver, spleen, kidney, heart muscle, skeletal muscle, eye lens, endothelial cells, smooth muscle cells and biomatrix to promote the adhesion of tissue correspondingly selected from said tissue group.
CA002163250A 1993-06-03 1994-06-03 Biological adhesive composition and method of promoting adhesion between tissue surfaces Abandoned CA2163250A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US071,528 1993-06-03
US08/071,528 US5549904A (en) 1993-06-03 1993-06-03 Biological adhesive composition and method of promoting adhesion between tissue surfaces

Publications (1)

Publication Number Publication Date
CA2163250A1 true CA2163250A1 (en) 1994-12-22

Family

ID=22101910

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002163250A Abandoned CA2163250A1 (en) 1993-06-03 1994-06-03 Biological adhesive composition and method of promoting adhesion between tissue surfaces

Country Status (10)

Country Link
US (2) US5549904A (en)
EP (1) EP0702572B1 (en)
JP (1) JP3483255B2 (en)
AT (1) ATE234643T1 (en)
AU (2) AU7051194A (en)
CA (1) CA2163250A1 (en)
DE (1) DE69432300T2 (en)
ES (1) ES2194869T3 (en)
TW (1) TW404836B (en)
WO (1) WO1994028949A1 (en)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936035A (en) * 1988-11-21 1999-08-10 Cohesion Technologies, Inc. Biocompatible adhesive compositions
US6197325B1 (en) 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US7229959B1 (en) * 1990-11-27 2007-06-12 The American National Red Cross Supplemented fibrin matrix delivery systems
US6117425A (en) 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
US6054122A (en) 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
JPH07328108A (en) * 1994-06-10 1995-12-19 Ajinomoto Co Inc Organic tissue adhesive and blood coagulant
CN1165539A (en) * 1994-09-29 1997-11-19 味之素株式会社 Modification of peptide and protein
US7883693B2 (en) 1995-12-18 2011-02-08 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
US6833408B2 (en) 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
EP2111876B1 (en) 1995-12-18 2011-09-07 AngioDevice International GmbH Crosslinked polymer compositions and methods for their use
US6458889B1 (en) 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
JP2002500898A (en) * 1997-08-15 2002-01-15 チルドレンズ メディカル センター コーポレーション Osteopontin coating surface and its use
US6114119A (en) * 1997-08-29 2000-09-05 Wisconsin Alumni Research Foundation Transglutaminase and gene encoding same
WO1999022747A1 (en) * 1997-10-30 1999-05-14 The General Hospital Corporation Bonding of cartilaginous matrices using isolated chondrocytes
US20030099620A1 (en) * 1997-10-30 2003-05-29 The General Hospital Corporation Bonding of cartilaginous matrices using isolated chondrocytes
US6190896B1 (en) 1997-11-14 2001-02-20 Bassam M. Fraij Active human cellular transglutaminase
JP2002507403A (en) * 1998-03-26 2002-03-12 ザ・ジェネラル・ホスピタル・コーポレイション Sielin and its use
US20020022588A1 (en) * 1998-06-23 2002-02-21 James Wilkie Methods and compositions for sealing tissue leaks
US6190815B1 (en) * 1998-08-11 2001-02-20 Xerox Corporation Toner compositions
US7241730B2 (en) * 1998-08-27 2007-07-10 Universitat Zurich Enzyme-mediated modification of fibrin for tissue engineering: fibrin formulations with peptides
US6197061B1 (en) 1999-03-01 2001-03-06 Koichi Masuda In vitro production of transplantable cartilage tissue cohesive cartilage produced thereby, and method for the surgical repair of cartilage damage
US6463335B1 (en) 1999-10-04 2002-10-08 Medtronic, Inc. Temporary medical electrical lead having electrode mounting pad with biodegradable adhesive
AU775590B2 (en) 2000-01-25 2004-08-05 Edwards Lifesciences Corporation Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia
GB0011356D0 (en) * 2000-05-12 2000-06-28 Univ Nottingham Trent Medical implant materials
US6685626B2 (en) 2001-02-02 2004-02-03 Regeneration Technologies, Inc. Compositions, devices, methods, and kits for induction of adhesions
US20060094112A1 (en) * 2001-03-07 2006-05-04 Omotunde Babalola Biological scaffold
EP1416876B1 (en) * 2001-07-16 2011-03-23 DePuy Products, Inc. Porous delivery scaffold and method
US8815793B2 (en) * 2001-07-20 2014-08-26 Northwestern University Polymeric compositions and related methods of use
US7618937B2 (en) * 2001-07-20 2009-11-17 Northwestern University Peptidomimetic polymers for antifouling surfaces
US7858679B2 (en) * 2001-07-20 2010-12-28 Northwestern University Polymeric compositions and related methods of use
US7476257B2 (en) * 2001-09-15 2009-01-13 Rush University Medical Center Methods to engineer stratified cartilage tissue
US20030165473A1 (en) * 2001-11-09 2003-09-04 Rush-Presbyterian-St. Luke's Medical Center Engineered intervertebral disc tissue
ES2223227B1 (en) 2002-05-31 2006-04-16 Consejo Sup. Investig. Cientificas NUCLEOTIDE SEQUENCE OF CODING CORN OF A PROTEIN WITH TRANSGLUTAMINASE ACTIVITY, AND ITS USE.
US8911831B2 (en) * 2002-07-19 2014-12-16 Northwestern University Surface independent, surface-modifying, multifunctional coatings and applications thereof
US7163545B2 (en) * 2002-07-29 2007-01-16 Mayo Foundation For Medical Education And Research Spinal cord surgical implant
WO2004042068A2 (en) * 2002-10-31 2004-05-21 Northwestern University Injectable and bioadhesive polymeric hydrogels as well as related methods of enzymatic preparation
US20040225077A1 (en) * 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
EP1583561A3 (en) * 2002-12-30 2005-12-07 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
JP2004283371A (en) * 2003-03-20 2004-10-14 Nagoya Industrial Science Research Inst Medical material
US7067123B2 (en) 2003-04-29 2006-06-27 Musculoskeletal Transplant Foundation Glue for cartilage repair
US7901457B2 (en) 2003-05-16 2011-03-08 Musculoskeletal Transplant Foundation Cartilage allograft plug
EP1684671B1 (en) 2003-10-06 2020-09-30 Medtronic 3F Therapeutics, Inc. Minimally invasive valve replacement system
US7101396B2 (en) 2003-10-06 2006-09-05 3F Therapeutics, Inc. Minimally invasive valve replacement system
ATE515245T1 (en) 2003-12-11 2011-07-15 Isto Technologies Inc PARTICLE CARTILAGE SYSTEM
US8067031B2 (en) 2004-04-28 2011-11-29 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
JP4767252B2 (en) 2004-06-14 2011-09-07 ヌームアールエックス・インコーポレーテッド Lung access device
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US7608579B2 (en) * 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US7553810B2 (en) * 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US7468350B2 (en) 2004-06-16 2008-12-23 Pneumrx, Inc. Glue composition for lung volume reduction
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US20050288684A1 (en) * 2004-06-16 2005-12-29 Aronson Nathan A Method of reducing collateral flow in a portion of a lung
US20050281739A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue using compositions
US20050281798A1 (en) * 2004-06-16 2005-12-22 Glen Gong Targeting sites of damaged lung tissue using composition
US20050288796A1 (en) * 2004-06-23 2005-12-29 Hani Awad Native soft tissue matrix for therapeutic applications
US7766891B2 (en) 2004-07-08 2010-08-03 Pneumrx, Inc. Lung device with sealing features
CA2570261C (en) 2004-07-08 2014-06-10 Pneumrx, Inc. Pleural effusion treatment device, method and material
CA2581093C (en) 2004-09-17 2014-11-18 Angiotech Biomaterials Corporation Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use
US7837740B2 (en) 2007-01-24 2010-11-23 Musculoskeletal Transplant Foundation Two piece cancellous construct for cartilage repair
US20060111778A1 (en) * 2004-10-29 2006-05-25 Michalow Alexander E Methods of promoting healing of cartilage defects and method of causing stem cells to differentiate by the articular chondrocyte pathway
JP4874259B2 (en) 2004-11-23 2012-02-15 ヌームアールエックス・インコーポレーテッド Steerable device for accessing the target site
US7815926B2 (en) * 2005-07-11 2010-10-19 Musculoskeletal Transplant Foundation Implant for articular cartilage repair
WO2007025290A2 (en) 2005-08-26 2007-03-01 Isto Technologies, Inc. Implants and methods for repair, replacement and treatment of joint disease
EP1926459B1 (en) 2005-09-19 2015-01-07 Histogenics Corporation Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
US7732539B2 (en) * 2006-02-16 2010-06-08 National Science Foundation Modified acrylic block copolymers for hydrogels and pressure sensitive wet adhesives
US8157837B2 (en) 2006-03-13 2012-04-17 Pneumrx, Inc. Minimally invasive lung volume reduction device and method
US8888800B2 (en) 2006-03-13 2014-11-18 Pneumrx, Inc. Lung volume reduction devices, methods, and systems
US9402633B2 (en) 2006-03-13 2016-08-02 Pneumrx, Inc. Torque alleviating intra-airway lung volume reduction compressive implant structures
DE602007011920D1 (en) * 2006-05-26 2011-02-24 Baxter Healthcare Sa INJECTABLE FILLER FOR BONE HOLLOW ROOMS
JP5298010B2 (en) * 2006-05-26 2013-09-25 バクスター・インターナショナル・インコーポレイテッド Fibrin composition for injection for bone formation
DE102006033167A1 (en) 2006-07-10 2008-01-24 Gelita Ag Use of gelatin and a crosslinking agent for the preparation of a crosslinking medical adhesive
DE102006033168A1 (en) 2006-07-10 2008-01-17 Gelita Ag Use of gelatin and a crosslinking agent for the preparation of a crosslinking therapeutic composition
AU2007283772B2 (en) 2006-08-04 2013-03-07 Kensey Nash Corporation Biomimetic compounds and synthetic methods therefor
WO2008091386A2 (en) * 2006-08-04 2008-07-31 Northwestern University Biomimetic modular adhesive complex: material, methods and applications therefore
US20100297218A1 (en) * 2006-09-20 2010-11-25 Pneumrx, Inc. Tissue adhesive compositions and methods thereof
DK176786B1 (en) * 2006-12-08 2009-08-24 Dat Schaub A M B A A process for joining pieces of natural casing
US7935363B2 (en) * 2006-12-12 2011-05-03 Synthasome, Inc. Composite material for tissue repair
US8133484B2 (en) 2006-12-15 2012-03-13 Lifebond Ltd Hemostatic materials and dressing
WO2008076407A2 (en) 2006-12-15 2008-06-26 Lifebond Ltd. Gelatin-transglutaminase hemostatic dressings and sealants
US20080154233A1 (en) * 2006-12-20 2008-06-26 Zimmer Orthobiologics, Inc. Apparatus for delivering a biocompatible material to a surgical site and method of using same
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
WO2008089032A1 (en) * 2007-01-11 2008-07-24 Northwestern University Fouling resistant coatings and methods of making same
US8673286B2 (en) 2007-04-09 2014-03-18 Northwestern University DOPA-functionalized, branched, poly(aklylene oxide) adhesives
US8383092B2 (en) * 2007-02-16 2013-02-26 Knc Ner Acquisition Sub, Inc. Bioadhesive constructs
US10278947B2 (en) 2007-02-28 2019-05-07 Orthopeutics, L.P. Crosslinker enhanced repair of connective tissues
US8435551B2 (en) 2007-03-06 2013-05-07 Musculoskeletal Transplant Foundation Cancellous construct with support ring for repair of osteochondral defects
WO2008128075A1 (en) 2007-04-12 2008-10-23 Isto Technologies, Inc. Compositions and methods for tissue repair
JP5907656B2 (en) * 2007-04-23 2016-04-26 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated Fibrin composition comprising a strontium compound
EP2265220A1 (en) 2008-03-05 2010-12-29 Musculoskeletal Transplant Foundation Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles
WO2009153751A2 (en) * 2008-06-18 2009-12-23 Lifebond Ltd A method for enzymatic cross-linking of a protein
US20110112573A1 (en) * 2008-06-18 2011-05-12 Orahn Preiss Bloom Methods and devices for use with sealants
CN102124058B (en) * 2008-06-18 2014-05-28 生命连结有限公司 Improved cross-linked compositions
US9173669B2 (en) 2008-09-12 2015-11-03 Pneumrx, Inc. Enhanced efficacy lung volume reduction devices, methods, and systems
US20100274362A1 (en) * 2009-01-15 2010-10-28 Avner Yayon Cartilage particle tissue mixtures optionally combined with a cancellous construct
JP5809621B2 (en) 2009-05-18 2015-11-11 ヌームアールエックス・インコーポレーテッド Implants for treating a patient's lungs
US9597430B2 (en) * 2009-07-31 2017-03-21 Synthasome, Inc. Synthetic structure for soft tissue repair
US20110130465A1 (en) * 2009-12-01 2011-06-02 Nerites Corporation Coatings for prevention of biofilms
AU2010334412B2 (en) 2009-12-22 2016-02-04 Lifebond Ltd Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices
US9163212B2 (en) 2010-01-25 2015-10-20 Warsaw Orthopedic, Inc. Osteogenic cell delivery matrix
ES2567174T3 (en) 2010-08-05 2016-04-20 Lifebond Ltd Dry composition in dressings and wound adhesives
US9549760B2 (en) 2010-10-29 2017-01-24 Kyphon Sarl Reduced extravasation of bone cement
CA2817215C (en) 2010-11-09 2017-05-09 Knc Ner Acquisition Sub, Inc. Adhesive compounds for use in hernia repair
AU2012322814A1 (en) * 2011-10-11 2014-05-29 Zimmer Knee Creations, Inc. Methods and instruments for subchondral treatment of osteoarthritis in a small joint
US8999376B2 (en) 2012-02-03 2015-04-07 Xcede Technologies, Inc. Tissue patch
US20140178343A1 (en) 2012-12-21 2014-06-26 Jian Q. Yao Supports and methods for promoting integration of cartilage tissue explants
US10390838B1 (en) 2014-08-20 2019-08-27 Pneumrx, Inc. Tuned strength chronic obstructive pulmonary disease treatment
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
US9833538B2 (en) 2015-08-07 2017-12-05 Xcede Technologies, Inc. Adhesive compositions and related methods
US10588998B2 (en) 2015-08-07 2020-03-17 Xcede Technologies, Inc. Adhesive compositions and related methods
US9540548B1 (en) 2015-08-07 2017-01-10 Xcede Technologies, Inc. Adhesive compositions and related methods
WO2017223462A1 (en) * 2016-06-24 2017-12-28 President And Fellows Of Harvard College Composition and method for adhering biomaterials to a target surface
WO2018140853A1 (en) 2017-01-30 2018-08-02 Lifecell Corporation Transglutaminase treated products
AU2018212909B2 (en) * 2017-01-30 2023-12-14 Lifecell Corporation Tissue matrix materials and enzymatic adhesives
CN110573188B (en) * 2017-01-30 2022-02-01 生命细胞公司 Device comprising a muscle matrix, method for production and use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2949407A1 (en) * 1979-12-07 1981-06-11 Boehringer Mannheim Gmbh, 6800 Mannheim METHOD FOR OBTAINING (ALPHA) -2-SB-GLYCOPROTEIN
DE3113986A1 (en) * 1981-04-07 1982-10-21 Robert Bosch Gmbh, 7000 Stuttgart DEVICE FOR CONTROLLING THE IDLE SPEED OF AN INTERNAL COMBUSTION ENGINE
US4582794A (en) * 1982-09-15 1986-04-15 The University Of Arizona Foundation Method of determining polyamine content of biological fluids
US5037816A (en) * 1984-11-02 1991-08-06 The General Hospital Corporation Method of treating psoriasis
US4728643A (en) * 1984-11-02 1988-03-01 The General Hospital Corporation Method of treating psoriasis
AU2423988A (en) * 1987-08-17 1989-03-09 Liposome Company, Inc., The A sponge enzyme having transglutaminase-like activity
US4968713A (en) * 1989-07-31 1990-11-06 Merck & Co., Inc. Certain imidazole compounds as transglutaminase inhibitors
AU1268192A (en) * 1991-01-04 1992-08-17 Board Of Regents, The University Of Texas System Cloning and expression of tissue transglutaminases
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5270300A (en) * 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone

Also Published As

Publication number Publication date
AU8305598A (en) 1999-04-29
ATE234643T1 (en) 2003-04-15
WO1994028949A1 (en) 1994-12-22
DE69432300D1 (en) 2003-04-24
DE69432300T2 (en) 2004-02-12
ES2194869T3 (en) 2003-12-01
EP0702572B1 (en) 2003-03-19
JP3483255B2 (en) 2004-01-06
TW404836B (en) 2000-09-11
US5549904A (en) 1996-08-27
AU7051194A (en) 1995-01-03
JPH08510943A (en) 1996-11-19
US5736132A (en) 1998-04-07
EP0702572A1 (en) 1996-03-27

Similar Documents

Publication Publication Date Title
EP0702572B1 (en) Biological adhesive composition and method of promoting adhesion between tissue surfaces
Jürgensen et al. A new biological glue for cartilage-cartilage interfaces: tissue transglutaminase
EP0569541B1 (en) Growth factor containing matrix for the treatment of cartilage lesions
Brittberg et al. Autologous chondrocytes used for articular cartilage repair: an update.
EP0993311B1 (en) Compositions containing thrombin and microfibrillar collagen, and methods for preparation and use thereof
EP2175869B1 (en) Compositions for repair of lesions in cartilage and bone
CA2756818C (en) Method of tissue repair
US20030003153A1 (en) Reinforced matrices
US7560432B2 (en) In situ method for treatment and repair of meniscal injuries
US20060069011A1 (en) Method for treatment and repair of meniscal injuries
MX2007008319A (en) Supplemented matrices for the repair of bone fractures.
Heath et al. Involvement of tissue transglutaminase in the stabilisation of biomaterial/tissue interfaces important in medical devices
Kurnaz et al. Effect of platelet-rich plasma and platelet-rich fibrin matrix on healing of vertical meniscal tears in a rabbit model
JP2001514050A (en) Fibrinogen-based tissue adhesive
Orr et al. Attachment of periosteal grafts to articular cartilage with fibrin sealant
Evans Transglutaminases as bonding agents for use in cartilage repair
US20040110686A1 (en) Methods and compositions for enhancing fibroblast migration
WOUND A. SUGITACHI and I. SAKAMOTO
CA2247133A1 (en) Tissue sealant compositions and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued